Tag Archives: SYRS

H.C. Wainwright Remains a Hold on Syros Pharmaceuticals (SYRS)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report), with a price target of $10. The company’s shares closed yesterday at $6.90. Fein commented: “Our price target of

Roth Capital Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)

Roth Capital analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $6.81, close to its 52-week low of $6.25. Marango

Syros Pharmaceuticals (SYRS) Received its Third Buy in a Row

After JMP Securities and Oppenheimer gave Syros Pharmaceuticals (NASDAQ: SYRS) a Buy rating last month, the company received another Buy, this time from Roth Capital. Analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals today and set a price

Analysts Are Bullish on Top Healthcare Stocks: Syros Pharmaceuticals (SYRS), Argenx Se (ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS) and Argenx Se (NASDAQ:ARGX) with bullish sentiments. Syros Pharmaceuticals (SYRS) Oppenheimer analyst Leah R. Cann maintained a Buy rating

Syros Pharmaceuticals (SYRS) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $10. The company’s shares closed yesterday at $11.57. Fein noted: “Our price target of $10/share ($3.38 from tamibarotene +

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (NASDAQ: SYRS), Melinta Therapeutics Inc (NASDAQ: MLNT) and Vericel Corp (NASDAQ: VCEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS), Melinta Therapeutics Inc (NASDAQ:MLNT) and Vericel Corp (NASDAQ:VCEL) with bullish sentiments. Syros Pharmaceuticals (SYRS) Oppenheimer analyst Leah R. Cann